Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies

Anti-Cancer Drugs

Volumn 10, Issue SUPPL. 1, 1999, Pages

  Armand, Jean Pierre ^a   Cunningham, David ^b   Van Cutsem, Eric ^c   Misset, Jean Louis ^d   Kohne, Claus Henning ^e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HÔPITAL PAUL BROUSSE   (France)

^e UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

5 fluorouracil; Colorectal cancer; Docetaxel irinotecan; Oxaliplatin; Ralititrexed

Indexed keywords

CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033369297     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911001-00002     Document Type: Conference Paper

References (45)

1. Creemers GJ, Wanders J, Gamucci T, et al. Topotecan in colorectal cancer: a phase II study of the EORTC Early Clinical Trials Group. Ann Oncol 1995; 6: 844-6.
2. Creemers GJ, Gerrits CJ, Schellens JH, et al. Phase II and pharmacological study of topotecan administered as a 21 day continuous infusion to patients with colorectal cancer. J Clin Oncol 1996; 14: 2540-50.
3. Benedetti JK, Burris HA, Balcerzak SP, Macdonald JS. Phase II trial of topotecan in advanced gastric cancer: a Southwest Oncology Group Study. Invest New Dnigs 1997; 15: 261-4.
4. Saltz LB, Schwartz GK, Ilson DH, Quan V, Kelsen DP. A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. Am J Clin Ontol 1997; 20: 621-5.
5. Pazdur R, Diaz-Canton E, Ballard WP, et al. Phase II trial of 9-aminocamptothecin administered as a 72 h continuous infusion in metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2905-9.
6. Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann NY-Acad SCI 1996; 803: 224-30.
7. Stehlin JS, Giovanella BC, Natelson EA, et al. Clinical investigations of RFS 2000 (9-nitro-20-(S)-Camptothecin - 9NC) in patients with advanced pancreatic carcinoma. Proc Am Soc Clin Oncol 1998; 17: 263a (abstr 1012).
8. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with flourouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
9. Fages B, Cote C, Gruia G, et al. Tumor response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: analysis of data in 455 5-FU resistant patients treated with CPT-11. Proc Am Soc Clin Oncol 1997; 16: 288a (abstr 1022).
10. Rothenherg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 11228-35.
11. Van Cutsem F., Rougier P, Droz JP, et al. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer resistant to 5-FU. Proc Am Soc Clin Oncol 1997; 16: 268a (abstr 950).
12. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, et al. Clinical activity and benefits of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35: 54-9.
13. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
14. Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
15. Cunningham D, Zalcberg JR, Rath U, et al. Final results of randomized trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996; 7: 961-5.
16. Cocconi D, Cunningham D, Van Cutsem E, et al. Open randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 1998; 16: 2943-52.
17. Kerr DJ. Clinical efficacy of Tomudex (raltitrexed) in advanced colorectal cancer. Anti-Cancer Drugs 1997; 8: S11-5 (suppl 2).
18. Fujii S, Ikenaka K, Fukushima M, et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil 1-(-2-tetrahydrofuryl)-5-fluorouracil. Gan To Kagaku Ryobo 1978; 69: 763-72.
19. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-300.
20. Saltz LB, Leichman CG, Young CW, et al. A Fixed-ratio combination of uracil and ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995; 75: 782-85.
21. Findlay M, Van Cutsem E, Kocha W, et al. A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancers. Proc Am Soc Clin Oncol 1997; 16: 227a (abstr).
22. Vanhoefer U, Harstrick A, Köhne C-H, et al. Phase I study of weekly schedule of irinotecan, high dose leucovorin and infusional fluorouracil as first-line chemotherapy in advanced colorectal cancer. J Clin Oncol 1999; 17: 907-13.
23. Ducreux M, Rougier Ph, Ychou M, et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ('De Gramont' regimen) every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure. Proc Am Soc Clin Oncol 1997; 16: 234a (abstr 823).
24. Rougier P, Ychou M, Seitz JF, et al. Phase I/II study of CPT-11 in combination with LV2FU5 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5FU failure. Eur J Cancer 1997; 33: S169 (abstr 756) (suppl 8).
25. th NCI-EORTC Conf, Amsterdam 1998: abstr 261.
26. Van Cutsem E, Pozzo C, Starkhammer H, et al. A phase II study of irinotecan alternated with five day bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 11: 1199-204.
27. Rothenberg ML, Pazdur R, Rowinsky EK, et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1997; 16: 266a (abstr 944).
28. Douillard JY, Cunningham D, Roth AD, et al. A randomized phase III trial comparing irinotecan (IRI) + 5FU/folinic acid (FA) to the same schedule of 5FU/FA in patients (pts) with metastatic colorectal cancer (MCRC) as front line chemotherapy (CT). Proc Am Soc Clin Oncol 1999; 18: 233a (abstract 899).
29. Woynarwski JM, Chapman WG, Napier C, et al. Oxaliplatin effects on naked and intracellular DNA. Proc Am Soc Clin Oncol 1997; 38: 311 (abstr).
30. Becouarn Y, Ychou M, Ducreaux M, et al. Oxaliplatin (L-OHP) as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc Am Soc Clin Oncol 1997; 16: 229a (abstr).
31. Machover B, Diaz Rubio E, de Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinomas who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
32. Raymond E, Djeloul S, Buquet-Fagot C, et al. Oxaliplatin (L-OHP) and cisplatin (CDDP) in combination with 5FU, specific thymidylate synthase (TS) inhibitors (AG337, ZD1694), and topoisomerase I (topo-I) inhibitors (SN38, CPT-11) in human colonic, ovarian and breast cancers. Proc Am Soc Clin Oncol 1996; 37: 291 (abstr).
33. Goldwasser F, Chouaki N, Buthaud M, et al. CPT-11 oxaliplatin (L-OHP) every two weeks: a phase I study in patients with advanced digestive tumors. Proc Am Soc Clin Oncol 1998; 17: 242a (abstr 927).
34. Cvitkovic EF, Wasserman E, Riofrio M, et al. CPT-11/ oxaliplatin (L-OHP): thymidylate synthase (TS) independent combination with efficacy in 5-FU refractory colorectal cancer (CRC) patients (PTS). Proc Am Soc Clin Oncol 1998; 17: 278a (abstr 1068).
35. Wasserman E, Kalla S, Misset JL, et al. Oxaliplatin (L-OHP) and irinotecan (CPT-II) phase I/II studies: results in 5-FU refractory (FR) colorectal cancer (CRC) patients (pts). Proc Am Soc Clin Oncol 1999; 18: 238a (abstract 913).
36. Scheithauer W, Konnek S, Raderen M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/ leucovorin pretreated colorectal cancer. J Clin Oncol/1999; 17: 902-6.
37. Sulkes A, Smythe J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 1994; 70: 380-3.
38. Tagushi T. An early phase II clinical study with RP 56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Jpn J Cancer Chemother 1994; 21: 2431-7.
39. Wilke H, Vanhoefer U, Harstrick A, et al. Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998; 17: 305a (abstr 1177).
40. rd European Society for Medical Oncology Meeting. Athens, Greece 1998: abstr 233p.
41. Roth AD, Maibach R, Martinelli G, et al. Taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC): an active drug combination. Proc Am Soc Clin Oncol 1998; 17: 283a (abstr 1088).
42. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033-8.
43. rd European Society for Medical Oncology Meeting. Athens, Greece 1998: abstr 2190p.
44. Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 3: 921-7.
45. Boku N, Ohtsu A, Shimada K, et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer. Proc Am Soc Clin Oncol 1997; 16: 264a (abstr 936).